在耐火性皮肤肌炎和抗合成酶综合征中使用Anifrolumab
Ryan Bonaventure Soares1, Jihad Ben Gabr2, Mark Ash3
1Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
作为1型干扰素受体抑制剂的阿尼弗罗卢马布在治疗耐火性皮肤肌炎 (DM) 和抗合成酶综合征方面表现有前途. 本案例报告详细介绍了对标准疗法无反应的患者的显著改善,突出了针对性治疗的潜力.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 皮肤肌肉炎 (DM) 和抗合成酶综合征是罕见的自身免疫性炎症性肌肉病变.
- 这些情况涉及皮肤和肌肉炎症,通常具有全身影响.
- 耐药病例带来了治疗挑战.
研究的目的:
- 报告阿尼弗罗卢马布在患有耐火性DM/抗合成酶综合征的患者中的疗效.
- 探索用于炎症性肌肉病的新型治疗策略.
- 调查干扰素 (IFN) 轴在DM病变发生过程中的作用.
主要方法:
- 一个29岁的女性患有耐火性DM/抗合成酶综合征的病例报告.
- 最初的治疗包括甲状腺素,普雷尼松,静脉注射免疫球蛋白 (IVIg) 和托法西替尼.
- 随后的治疗包括IVIg,阿普雷米拉斯和非标签的阿尼弗罗卢马布.
主要成果:
- 患者表现出经典的DM皮肤表现,但肌肉病变最小.
- 传统疗法没有效果,疾病进展.
- 与anifrolumab的联合治疗导致肌肉病变和皮肤病变在5个月内显著改善.
结论:
- 针对1型干扰素受体的阿尼弗罗卢马布显示出作为耐火性DM的向治疗的潜力.
- 这一案例凸显了IFN途径在DM病原和治疗向中的重要性.
- 对阿尼弗罗卢马布和其他针对性治疗在炎症性肌肉病变中进行进一步的研究是有必要的.
更多相关视频
10:05Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
Published on: January 17, 2018
08:33Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
相关概念视频
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
